Efficacy of dupilumab on chronic rhinosinusitis with nasal polyps and concomitant asthma in biologic-naive and biologic-pretreated patients

Objectives Dupilumab, an anti-IL-4 receptor monoclonal antibody (mAb), was recently approved for the treatment of severe chronic rhinosinusitis with nasal polyps (CRSwNP). The main objective of this study was to assess whether previous exposure to biological treatment affected the clinical outcomes...

Celý popis

Podrobná bibliografie

Hlavní autoři:	María Sandra Domínguez-Sosa, María Soledad Cabrera-Ramírez, Miriam del Carmen Marrero-Ramos, Delia Dávila-Quintana, Carlos Cabrera-López, Heleia González Cuervo, Jesús Javier Benítez del Rosario, Teresa Carrillo-Díaz
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Taylor & Francis Group 2024-12-01
Edice:	Annals of Medicine
Témata:	Chronic rhinosinusitis nasal polyps dupilumab monoclonal antibody perennial allergen sensitization
On-line přístup:	https://www.tandfonline.com/doi/10.1080/07853890.2024.2411018
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!